background: early diagnosis of albuminuria and the prevention of its progression to macroalbuminuria and diabetic nephropathy are crucial. angiotensin converting enzyme inhibitors (aceis) and antagonists of angiotensin ii receptors type i (arbs) are currently used as first-line treatment for albuminuria in these patients. the present study was conducted to assess the efficacy of addition of spi...

220 ABSTRACT: Angiotensin-converting enyzme inhibitors (ACEIs) are commonly used to treat cardiovascular disorders. The use of ACEIs for hypertension is well established, although these agents have not proven to be superior to other antihypertensive agents. The use of ACEIs in heart failure is also well established, and has proven to reduce morbidity and mortality. ACEIs are now routinely used ...

BACKGROUND Cognitive improvement has been reported in patients receiving centrally acting angiotensin-converting enzyme inhibitors (C-ACEIs). AIMS To compare cognitive decline and survival after diagnosis of Alzheimer's disease between people receiving C-ACEIs, non-centrally acting angiotensin-converting enzyme inhibitors (NC-ACEIs), and neither. METHOD Routine Mini-Mental State Examination...

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-2 receptor blockers (ARBs) are used extensively in the treatment of arterial hypertension. There is a widespread belief that these drugs contraindicated patients with underlying aortic stenosis due to their vasodilatory effect, which could result hypotension syncope. Nonetheless, may significantly benefit such proven cardioprotect...

Studies on pharmacological mechanisms demonstrated that a strategy of dual renin-angiotensin system (RAS) blockade may have synergistic effect in the treatment cardiorenal diseases and reduce adverse reactions. However, some previous clinical studies reported RAS did not significantly benefit many patients with increased risk hyperkalemia, hypotension renal function damage. Therefore, current g...

The discovery of captopril, the prototype of orally active angiotensin-converting enzyme inhibitors (ACEIs), represented a major breakthrough in the treatment of cardiovascular diseases. Currently, captopril has four important indications: hypertension, congestive heart failure, acute myocardial infarction, and diabetic nephropathy. After the discovery of captopril, several new ACEIs were devel...

BACKGROUND Rheumatoid arthritis (RA) is regarded as a high risk factor for myocardial infarction. Hypertension is a major modifiable risk factor contributing to increased risk of myocardial infarction (MI). Dual blood pressure (BP)-lowering and anti-inflammatory effect of renin-angiotensin-system (RAS) inhibitors may possess protective effect from MI in RA population. However, treatment of hype...

Background: Early diagnosis of albuminuria and the prevention of its progression to macroalbuminuria and diabetic nephropathy are crucial. Angiotensin converting enzyme inhibitors (ACEIs) and antagonists of angiotensin II receptors type I (ARBs) are currently used as first-line treatment for albuminuria in these patients. The present study was conducted to assess the efficacy of addition of spi...

Background and Aim: COVID-19 is an acute respiratory illness caused by the severe syndrome coronavirus 2 (SARS-CoV-2). A few studies with conflicting results have been performed to evaluate relationship between use of angiotensin system inhibitors outcomes. Therefore, this study was compare clinical paraclinical characteristics patients in two groups treated angiotensin-converting enzyme (ACEIs...

ctivation of the renin – angiotensin system (RAS) has a profound effect on the prognosis of patients with myocardial infarction and/or heart failure with reduced ejection fraction (HFREF), as proven by the beneficial effects of angiotensin-converting enzyme inhibitors (ACEIs).1 Because angiotensin II is produced in the ACE-dependent and -independent pathways,2 the addition of AT1 receptor block...